Clinical Trial Update: Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update investigating camrelizumab combined with apatinib in relapsed/refractory diffuse large B-cell lymphoma, covering Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Huiqiang Huang | Conditions: Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN